ArticlePharmacoEconomics2024
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Dong-Won Kang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ArticlePharmacoEconomics2024
Dong-Won Kang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.